PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Both companies show declining cash positions (-31.05% vs TRAW's -24.22%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Cash + STI yoy 1.25-1.5x TRAW's -24.22%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Other current assets growth < half of TRAW's 24.10%. David Dodd sees a leaner approach to short-term items.
-31.37%
1.25-1.5x TRAW's -23.39%. Bruce Berkowitz checks if strong current asset growth is used effectively.
76.50%
Below half TRAW's -41.18%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of TRAW's -30.43%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
1.25-1.5x TRAW's -23.40%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-21.72%
Similar yoy growth to TRAW's -28.32%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
1.1-1.25x TRAW's -17.73%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Above 1.5x TRAW's -14.08%. Michael Burry sees a potential leverage warning sign.
0.01%
Less than half of TRAW's -93.30%. David Dodd sees fewer share issuances vs. competitor.
-3.53%
≥ 1.5x TRAW's -1.44%. David Dodd sees higher yoy retained profits than competitor.
-5.52%
Less than half of TRAW's -40.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
Similar yoy to TRAW's -31.76%. Walter Schloss sees parallel net worth trends.
-30.47%
1.25-1.5x TRAW's -23.40%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
1.25-1.5x TRAW's 24.22%. Martin Whitman is wary of heavier net leverage vs. competitor.